Minakem Generic APIs Minakem Generic APIs

X

CAS 33288-71-0 manufacturers and suppliers on PharmaCompass

PharmaCompass
CAS 33288-71-0
Also known as: 33288-71-0, 5-methyl-n-(4-sulfamoylphenethyl)pyrazine-2-carboxamide, 2-[4-aminosulfonyl-phenyl]-ethyl-5-methylpyrazinecarboxamide, Glipizide related compound a, 5-methyl-n-(2-(4-sulfamoylphenyl)ethyl)pyrazine-2-carboxamide, Ebq9973hl9
Molecular Formula
C14H16N4O3S
Molecular Weight
320.37  g/mol
InChI Key
IMEZLHZLIANIAS-UHFFFAOYSA-N
FDA UNII
EBQ9973HL9

1 2D Structure

CAS 33288-71-0

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-methyl-N-[2-(4-sulfamoylphenyl)ethyl]pyrazine-2-carboxamide
2.1.2 InChI
InChI=1S/C14H16N4O3S/c1-10-8-18-13(9-17-10)14(19)16-7-6-11-2-4-12(5-3-11)22(15,20)21/h2-5,8-9H,6-7H2,1H3,(H,16,19)(H2,15,20,21)
2.1.3 InChI Key
IMEZLHZLIANIAS-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)N
2.2 Other Identifiers
2.2.1 UNII
EBQ9973HL9
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 33288-71-0

2. 5-methyl-n-(4-sulfamoylphenethyl)pyrazine-2-carboxamide

3. 2-[4-aminosulfonyl-phenyl]-ethyl-5-methylpyrazinecarboxamide

4. Glipizide Related Compound A

5. 5-methyl-n-(2-(4-sulfamoylphenyl)ethyl)pyrazine-2-carboxamide

6. Ebq9973hl9

7. 5-methyl-n-[2-(4-sulphamoylphenyl)ethyl]pyrazine-2-carboxamide

8. 4-[beta-(5-methylpyrazinyl-2-carboxamido)ethyl]benzene Sulfonamide

9. Pyrazinecarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methyl-

10. Unii-ebq9973hl9

11. Pyrazinecarboxamide, N-(2-(4-(aminosulfonyl)phenyl)ethyl)-5-methyl-

12. Glipizide Impurity A

13. Schembl7826309

14. Dtxsid00186914

15. {2-[4-aminosulphonyl-phenyl]-ethyl}-5-methylpyrazinecarboxamide

16. Bcp13823

17. N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-methyl-2-pyrazinecarboxamide

18. Zinc15013234

19. Akos007992962

20. Ac-15563

21. Glipizide Impurity A [ep Impurity]

22. Db-068799

23. Glipizide Ep Impurity A (usp Rc A)

24. Cs-0215413

25. Ft-0672110

26. Glipizide Related Compound A [usp-rs]

27. 288a710

28. A821712

29. Glipizide Related Compound A [usp Impurity]

30. Q27277096

31. 5-methyl-n-(4-sulfamoylphenethyl)-pyrazine-2-carboxamide

32. 4-[-(5-methylpyrazinyl-2-carboxamido)ethyl]benzene Sulfonamide

33. 4-[2-(5-methylpyrazine-2-carboxamide)ethyl]benzenesulfonamide

34. N-[4-(aminosulfonyl)phenethyl]-5-methyl-2-pyrazinecarboxamide

35. Pyrazinecarboxamide, 5-methyl-n-(p-sulfamoylphenethyl)-

36. [2-(4-sulphamoylphenyl) Ethyl] 5-methyl-pyrazine-2-carboxamide

37. 4-[?-(5-methylpyrazinyl-2-carboxamido)ethyl]benzene Sulfonamide

38. N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methylpyrazine-carboxamide

39. 4-(2-(5-methylpyrazine-2-carboxamido)ethyl)benzenesulfonamide

40. 4-(2-(5-methylpyrazinyl-2-carboxamido)ethyl)benzenesulfonamide

41. N-(2-((4-aminosulfonyl)phenyl)ethyl)-5-methyl-pyrazinecarboxamide

42. 4-(5-(3-methylbenzyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)benzoic Acid

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 320.37 g/mol
Molecular Formula C14H16N4O3S
XLogP3-0.5
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count5
Exact Mass320.09431156 g/mol
Monoisotopic Mass320.09431156 g/mol
Topological Polar Surface Area123 Ų
Heavy Atom Count22
Formal Charge0
Complexity469
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Flag China
Digital Content Digital Content
URL Supplier Web Content
2523-55-9
Glimepiride
Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary locat...
Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary located in National Cangzhou Lingang Economic and Technological Development Zone,Cangzhou City,Hebei Province. Senary cover an area of 67,000 square meters, and 300 professionals work there. Senary R&D organization recognized as the Hebei Provincial Engineering Technology Center is comprised of two R & D centers in Tianjin and Cangzhou, and it employs 80 experienced scientists in total. Senary focus on the development, production and sales of advanced pharmaceutical intermediates. Especially, Senary has leading technology and manufacturing capacity for diabetes drug intermediates. All intermediates of DPP4 and SGLT2 class drugs on market have been commercialized production. Senary has 150 sets of 50 ~ 8000L reactor with annual production capacity of 1,000 tons, which can handle both low and high temperature reactions within -100 ~ 240 ℃ range, all kinds of catalytic reactions within 0 ~ 5MPa pressure, and moisture and/or oxygen sensitive reactions. Senary also has expertise in chiral synthesis with leading technologies. The advanced sewage treatment system at Senery has processing capacity of 600 tons daily. Senary has an excellent team that has rich quality management experience.We have established a set of normative and perfect quality managment system,monitoring the whole process of risk assessment,R&D,transfer from pilot scale to commercial production,manufacturing,analysis and sales service. Senary will continue to dedicate on the field of pharmaceutical intermediates to provide the best service for domestic and foreign API pharmaceutical companies with high quality and timely supply of products.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag China
Digital Content Digital Content
URL Supplier Web Content
119018-29-0
Glimepiride
Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary locat...
Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary located in National Cangzhou Lingang Economic and Technological Development Zone,Cangzhou City,Hebei Province. Senary cover an area of 67,000 square meters, and 300 professionals work there. Senary R&D organization recognized as the Hebei Provincial Engineering Technology Center is comprised of two R & D centers in Tianjin and Cangzhou, and it employs 80 experienced scientists in total. Senary focus on the development, production and sales of advanced pharmaceutical intermediates. Especially, Senary has leading technology and manufacturing capacity for diabetes drug intermediates. All intermediates of DPP4 and SGLT2 class drugs on market have been commercialized production. Senary has 150 sets of 50 ~ 8000L reactor with annual production capacity of 1,000 tons, which can handle both low and high temperature reactions within -100 ~ 240 ℃ range, all kinds of catalytic reactions within 0 ~ 5MPa pressure, and moisture and/or oxygen sensitive reactions. Senary also has expertise in chiral synthesis with leading technologies. The advanced sewage treatment system at Senery has processing capacity of 600 tons daily. Senary has an excellent team that has rich quality management experience.We have established a set of normative and perfect quality managment system,monitoring the whole process of risk assessment,R&D,transfer from pilot scale to commercial production,manufacturing,analysis and sales service. Senary will continue to dedicate on the field of pharmaceutical intermediates to provide the best service for domestic and foreign API pharmaceutical companies with high quality and timely supply of products.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag China
Digital Content Digital Content
URL Supplier Web Content
32175-00-1
Glimepiride
Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary locat...
Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary located in National Cangzhou Lingang Economic and Technological Development Zone,Cangzhou City,Hebei Province. Senary cover an area of 67,000 square meters, and 300 professionals work there. Senary R&D organization recognized as the Hebei Provincial Engineering Technology Center is comprised of two R & D centers in Tianjin and Cangzhou, and it employs 80 experienced scientists in total. Senary focus on the development, production and sales of advanced pharmaceutical intermediates. Especially, Senary has leading technology and manufacturing capacity for diabetes drug intermediates. All intermediates of DPP4 and SGLT2 class drugs on market have been commercialized production. Senary has 150 sets of 50 ~ 8000L reactor with annual production capacity of 1,000 tons, which can handle both low and high temperature reactions within -100 ~ 240 ℃ range, all kinds of catalytic reactions within 0 ~ 5MPa pressure, and moisture and/or oxygen sensitive reactions. Senary also has expertise in chiral synthesis with leading technologies. The advanced sewage treatment system at Senery has processing capacity of 600 tons daily. Senary has an excellent team that has rich quality management experience.We have established a set of normative and perfect quality managment system,monitoring the whole process of risk assessment,R&D,transfer from pilot scale to commercial production,manufacturing,analysis and sales service. Senary will continue to dedicate on the field of pharmaceutical intermediates to provide the best service for domestic and foreign API pharmaceutical companies with high quality and timely supply of products.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag China
Digital Content Digital Content
URL Supplier Web Content
766-36-9
Glimepiride
Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary locat...
Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary located in National Cangzhou Lingang Economic and Technological Development Zone,Cangzhou City,Hebei Province. Senary cover an area of 67,000 square meters, and 300 professionals work there. Senary R&D organization recognized as the Hebei Provincial Engineering Technology Center is comprised of two R & D centers in Tianjin and Cangzhou, and it employs 80 experienced scientists in total. Senary focus on the development, production and sales of advanced pharmaceutical intermediates. Especially, Senary has leading technology and manufacturing capacity for diabetes drug intermediates. All intermediates of DPP4 and SGLT2 class drugs on market have been commercialized production. Senary has 150 sets of 50 ~ 8000L reactor with annual production capacity of 1,000 tons, which can handle both low and high temperature reactions within -100 ~ 240 ℃ range, all kinds of catalytic reactions within 0 ~ 5MPa pressure, and moisture and/or oxygen sensitive reactions. Senary also has expertise in chiral synthesis with leading technologies. The advanced sewage treatment system at Senery has processing capacity of 600 tons daily. Senary has an excellent team that has rich quality management experience.We have established a set of normative and perfect quality managment system,monitoring the whole process of risk assessment,R&D,transfer from pilot scale to commercial production,manufacturing,analysis and sales service. Senary will continue to dedicate on the field of pharmaceutical intermediates to provide the best service for domestic and foreign API pharmaceutical companies with high quality and timely supply of products.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY